Nurix Therapeutics Files 8-K for Regulatory Disclosure & Exhibits

Ticker: NRIX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1549595

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance, corporate-governance

TL;DR

**Nurix Therapeutics filed a routine 8-K for regulatory disclosure, nothing major.**

AI Summary

Nurix Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. This filing indicates that the company is maintaining compliance with SEC regulations and provides updated corporate information, such as its address at 1700 Owens Street, Suite 205, San Francisco, California 94158. For investors, this matters because it confirms Nurix's ongoing adherence to transparency requirements, which is a basic expectation for publicly traded companies like NRIX on the Nasdaq Global Market.

Why It Matters

This filing demonstrates Nurix Therapeutics' commitment to regulatory compliance and transparency, which is crucial for maintaining investor confidence and market integrity.

Risk Assessment

Risk Level: low — This 8-K is a standard regulatory filing and does not indicate any new material risks or changes to the company's operations.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material changes to Nurix Therapeutics' business operations or financial health, and would look for more substantive filings for investment decisions.

Key Players & Entities

FAQ

What is the purpose of Nurix Therapeutics, Inc.'s 8-K filing dated January 8, 2024?

The 8-K filing by Nurix Therapeutics, Inc. on January 8, 2024, is primarily for Regulation FD Disclosure and to include Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' sections.

What is the trading symbol and exchange for Nurix Therapeutics, Inc. Common Stock?

The Common Stock of Nurix Therapeutics, Inc. trades under the symbol NRIX and is registered on the Nasdaq Global Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.

What is the current business address of Nurix Therapeutics, Inc. as reported in this filing?

The current business address of Nurix Therapeutics, Inc. is 1700 Owens Street, Suite 205, San Francisco, California 94158, with a business phone number of (415) 660-5320, according to the 'BUSINESS ADDRESS' section.

What is the state of incorporation for Nurix Therapeutics, Inc.?

Nurix Therapeutics, Inc. is incorporated in Delaware, as specified under 'State or Other Jurisdiction of Incorporation or Organization'.

Does this 8-K filing indicate that Nurix Therapeutics, Inc. is an emerging growth company?

The filing includes a checkbox 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of t' but the provided text does not show whether the box is checked or not, so it cannot be definitively determined from this excerpt.

Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-08 07:03:31

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. As previously announced, on January 8, 2024, Nurix Therapeutics, Inc. (the "Company") will present an overview of the Company's performance in 2023 and its major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference (the "JPM Conference"). A copy of the Company's presentation materials for the JPM Conference is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Also on January 8, 2024, the Company issued the press release attached as Exhibit 99.2 hereto, which is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Nurix Therapeutics, Inc. investor presentation dated January 8, 2024. 99.2 Nurix Therapeutics, Inc. press release dated January 8 , 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing